» Articles » PMID: 37589705

A Cleaved METTL3 Potentiates the METTL3-WTAP Interaction and Breast Cancer Progression

Overview
Journal Elife
Specialty Biology
Date 2023 Aug 17
PMID 37589705
Authors
Affiliations
Soon will be listed here.
Abstract

-methyladenosine (mA) methylation of RNA by the methyltransferase complex (MTC), with core components including METTL3-METTL14 heterodimers and (WTAP), contributes to breast tumorigenesis, but the underlying regulatory mechanisms remain elusive. Here, we identify a novel cleaved form METTL3a (residues 239-580 of METTL3). We find that METTL3a is required for the METTL3-WTAP interaction, RNA mA deposition, as well as cancer cell proliferation. Mechanistically, we find that METTL3a is essential for the METTL3-METTL3 interaction, which is a prerequisite step for recruitment of WTAP in MTC. Analysis of mA sequencing data shows that depletion of METTL3a globally disrupts mA deposition, and METTL3a mediates mammalian target of rapamycin (mTOR) activation via mA-mediated suppression of TMEM127 expression. Moreover, we find that METTL3 cleavage is mediated by proteasome in an mTOR-dependent manner, revealing positive regulatory feedback between METTL3a and mTOR signaling. Our findings reveal METTL3a as an important component of MTC, and suggest the METTL3a-mTOR axis as a potential therapeutic target for breast cancer.

Citing Articles

The m6A revolution: transforming tumor immunity and enhancing immunotherapy outcomes.

Shi T, Zhang H, Chen Y Cell Biosci. 2025; 15(1):27.

PMID: 39987091 PMC: 11846233. DOI: 10.1186/s13578-025-01368-z.


Correlation between METTL3 overexpression and F-FDG uptake in patients with soft tissue sarcoma.

Wu T, Xie J, Feng H, Zhang H, Tao J, Chen B BMC Cancer. 2025; 25(1):27.

PMID: 39773621 PMC: 11708263. DOI: 10.1186/s12885-024-13419-8.


N6-Methyladenosine methylation modification in breast cancer: current insights.

Zhang G, Cheng C, Wang X, Wang S J Transl Med. 2024; 22(1):971.

PMID: 39468547 PMC: 11514918. DOI: 10.1186/s12967-024-05771-x.


Hypoxic stabilization of RIPOR3 mRNA via METTL3-mediated mA methylation drives breast cancer progression and metastasis.

Xiong J, Zhou Z, Jiang Y, Li Q, Geng Z, Guo J Oncogene. 2024; 43(47):3426-3441.

PMID: 39341989 DOI: 10.1038/s41388-024-03180-4.


Influence of RNA Methylation on Cancerous Cells: A Prospective Approach for Alteration of In Vivo Cellular Composition.

Rupareliya M, Shende P Adv Exp Med Biol. 2024; 1474():79-103.

PMID: 39259424 DOI: 10.1007/5584_2024_820.


References
1.
Manasanch E, Orlowski R . Proteasome inhibitors in cancer therapy. Nat Rev Clin Oncol. 2017; 14(7):417-433. PMC: 5828026. DOI: 10.1038/nrclinonc.2016.206. View

2.
Liu C, Corboy M, DeMartino G, Thomas P . Endoproteolytic activity of the proteasome. Science. 2002; 299(5605):408-11. PMC: 3516294. DOI: 10.1126/science.1079293. View

3.
Yankova E, Blackaby W, Albertella M, Rak J, De Braekeleer E, Tsagkogeorga G . Small-molecule inhibition of METTL3 as a strategy against myeloid leukaemia. Nature. 2021; 593(7860):597-601. PMC: 7613134. DOI: 10.1038/s41586-021-03536-w. View

4.
Yan C, Xiong J, Zhou Z, Li Q, Gao C, Zhang M . A cleaved METTL3 potentiates the METTL3-WTAP interaction and breast cancer progression. Elife. 2023; 12. PMC: 10435237. DOI: 10.7554/eLife.87283. View

5.
Livneh I, Moshitch-Moshkovitz S, Amariglio N, Rechavi G, Dominissini D . The mA epitranscriptome: transcriptome plasticity in brain development and function. Nat Rev Neurosci. 2019; 21(1):36-51. DOI: 10.1038/s41583-019-0244-z. View